Infliximab therapy for sarcoidosis (lupus pernio)

Academic Article

Abstract

  • Sarcoidosis is a chronic granulomatous disease of unknown aetiology in which the primary cytokine tumour necrosis factor (TNF)-α appears to play a major role. Older immune-modulating drugs including corticosteroids, antimalarials and thalidomide, as well as cytotoxic drugs with immune modulatory effects, have been used to control disease. We present a patient with severe mutilating cutaneous sarcoidosis (lupus pernio) who had showed only partial response to courses of a wide spectrum of immune modulators and cytotoxic therapies, and who had developed significant side-effects due to prolonged high-dose corticosteroids. However, the patient's cutaneous disease responded rapidly to the TNF-α inhibitor infliximab.
  • Published In

    Digital Object Identifier (doi)

    Author List

  • Haley H; Cantrell W; Smith K
  • Start Page

  • 146
  • End Page

  • 149
  • Volume

  • 150
  • Issue

  • 1